// App-Quantinova.ai

TPS5094 : A phase II trial of cemiplimab alone or in combination with standard of care chemotherapy in locally advanced or metastatic penile carcinoma (EPIC Trial).

Researchers

Presenter

  • Emily Renninson

Principal Investigators

  • Amarnath Challapalli

  • Emily Foulstone

  • Alicia Bravo

  • Alexandra Soundy

  • Mark Callaway

  • Alastair Thomson

  • Constantine Alifrangis

  • Mehran Afshar

  • Anna Tran

  • Balaji Venugopal

  • Paul White

  • Emil Cano

  • Anand Sharma

  • Amit Bahl

Medical Centers

  • Bristol Haematology and Oncology Centre, University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom

  • University Hospitals Bristol NHS Foundation Trust, Wells Somerset, United Kingdom

  • Royal Cornwall Hospital, Truro, United Kingdom

  • University College London Hospitals NHS Trust, London, United Kingdom

  • St. George's University Hospital, London, United Kingdom

  • The Christie NHS Foundation TRUST, Manchester, United Kingdom

  • Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom

  • University of the West of England, Bristol, United Kingdom

  • Mount Vernon Cancer Centre, Northwood, United Kingdom

  • University Hospitals Bristol NHS Foundation Trust - Bristol Haematology and Oncology Centre, Department of Oncology, Bristol, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Penile carcinoma

Biomarkers

  • N/A

Drug/Treatment

  • Cisplatin

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

  • Multiple Arm

  • Non Randomized

  • Multicenteric

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved